ARTBIO

ARTBIO is a clinical-stage radiopharmaceutical biotechnology company that focuses on developing a new class of alpha radioligand therapies (ART). The company's slogan "Empowering patient-centric advances in cancer care" reflects its unique patient-centric approach, which is built on a deep understanding of cancer biology and the necessary infrastructure for designing, manufacturing, and distributing therapies. Founded in 2021 and headquartered in the United States, ARTBIO recently secured a significant $90.00M Series A investment on 07 December 2023. The investors in this round were F-Prime Capital, Third Rock Ventures, and Omega Funds. The company operates in the Biotechnology, Health Care, Medical Devices, and Pharmaceutical industries, showcasing the breadth of its potential impact in the healthcare sector.